NeoGenomics to Present Eight Abstracts at ASCO 2026 Covering Multiomics Biomarkers and MRD Assay (briefglance.com)

• Eight abstracts at ASCO 2026 covering hematologic malignancies, solid tumors, and NGS insurance gaps.
• New biomarkers: B7-H3, CD137, EZH2, PRMT5.
• Launch of low-sample-input AML MRD flow assay.
• Updated corporate mission emphasizing personalized cancer treatment.

"NeoGenomics will present eight scientific abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). The research spans hematologic malignancies, solid-tumor genomic profiling, and real-world evidence on insurance coverage gaps for NGS testing. New biomarkers include B7-H3, CD137, EZH2, and PRMT5. The company introduces a low-sample-input AML MRD flow assay and updates its mission to focus on personalized cancer treatment decisions."